Stay updated with breaking news from Herbert Baraf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.
Phase III results back potential competitor for pegloticase-methotrexate treatment
Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.